Clinical Trial Update: Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating a 12-week regimen of telaprevir with pegylated interferon and ribavirin in treatment-naive and prior relapser chronic hepatitis C patie…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Pegylated interferon alfa-2a (Peginterferon alfa-2a)
• Ribavirin (ribavirin)
• Telaprevir (telaprevir)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Hepatitis C, Chronic | Phase 3 | Status: TERMINATED | Results posted: 2015-02-11